Stemline Therapeutics (STML) SL-401 Data at ASH Shows Consistent Efficacy in BPDCN - Jefferies
Tweet Send to a Friend
Jefferies analyst Biren Amin reiterated a Buy rating and $23 price target on Stemline Therapeutics (NASDAQ: STML) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
